Lilly’s Mounjaro (tirzepatide) demonstrated cardiovascular protection in a head-to-head trial EP News Bureau Aug 1, 2025 Mounjaro met the primary objective of non-inferiority vs. Trulicity with an 8 per cent lower rate of MACE-3 events, while…
